QUEST DIAGNOSTICS INC (DGX) Form 10-Q — Oct 23, 2026
Quest Diagnostics reported Q3 2026 net revenues of $3,097 million, up 10.0% year-over-year, with diluted EPS of $2.78 versus $2.16, a 28.7% increase. Operating income rose 24.2% to $479 million, and nine-month revenues reached $9,035 million, up 9.8%. Growth was driven by DIS volume up 14.5% (14.4% organic), of which 9.5 percentage points came from new relationships with Corewell Health and Fresenius Medical Care dialysis clinics. Excluding those, volume grew 5% and revenue per requisition rose 1.7%, though reported revenue per requisition fell 4.2% on routine-test mix from the new deals.
Key figures
- Eps
- 2.78
- Revenue
- 3097000000
- Guidance
- Company estimates approximately $550 million of 2026 capital expenditures
- Net Income
- 312000000
- Total Debt
- 5550000000
- Revenue Yoy
- 10.0%
- Total Assets
- 17221000000
- Cash Position
- 797000000
- Shares Outstanding
- 110019073
- Revenue 9mo
- 9035000000
- Dis Revenue Q3
- 3035000000
- Net Income 9mo
- 884000000
- Diluted EPS 9mo
- 7.86
- Dividend Per Share Q
- 0.86
- Operating Income Q3
- 479000000
- Share Buybacks 9mo
- 250000000
- Effective Tax Rate Q3
- 23.7%
- Operating Income Yo Y
- 24.2%
- Days Sales Outstanding
- 51
- Operating Cash Flow 9mo
- 1486000000
- Organic Volume Change Q3
- 14.4%
- Requisition Volume Change Q3
- 14.5%
- Buyback Authorization Remaining
- 1200000000
- Revenue Per Requisition Change Q3
- -4.2%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.